Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Summary

This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).

Timeline

Start

2022-09-27

Primary completion

2024-11-19

Completion

2024-11-19

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications